A Phase II Study Of Arsenic Trioxide In Patients With Adenocarcinoma Of The Pancreas Refractory To Gemcitabine
- Determine the objective response rate to arsenic trioxide in patients with pancreatic
cancer who have progressed after first-line treatment with a gemcitabine-containing
regimen when treated with arsenic trioxide.
- Determine the toxicity of this drug in these patients.
- Determine the duration of response, median and overall survival, and time to
progression in patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive arsenic trioxide IV over 1 hour on days 1-5. Courses repeat every 28 days
in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 9-12
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Hedy L. Kindler, MD
University of Chicago
United States: Federal Government
|University of Chicago Cancer Research Center||Chicago, Illinois 60637|
|Loyola University Medical Center||Maywood, Illinois 60153|
|Ingalls Memorial Hospital||Harvey, Illinois 60426|
|CCOP - Northern Indiana CR Consortium||South Bend, Indiana 46601|
|Fort Wayne Medical Oncology and Hematology, Incorporated||Fort Wayne, Indiana 46885-5099|
|Evanston Northwestern Health Care - Evanston Hospital||Evanston, Illinois 60201|
|Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph||Saint Joseph, Michigan 49085|
|Oncology/Hematology Associates of Central Illinois, P.C.||Peoria, Illinois 61602|
|Central Illinois Hematology Oncology Center||Springfield, Illinois 62701|
|Decatur Memorial Hospital Cancer Care Institute||Decatur, Illinois 62526|
|LaGrange Memorial Hospital||LaGrange, Illinois 60525|